TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

NCT01031589 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: TMC278 (Rilpivirine) LA; Placebo

Sponsor

Tibotec Pharmaceuticals, Ireland